Latest News

Kalbe and Amarox have made an adjustment to COVIFOR’s price in Indonesia

Kalbe and Amarox have made an adjustment to COVIFOR’s price in Indonesia

Press Release No. 039/KFCP-DIR/PR/X/20

Jakarta, Indonesia; 3 October 2020, Following inputs from Government, Healthcare Professionals, and Patients in these recent days, PT Kalbe Farma Tbk (Kalbe) together with PT Amarox Global Pharma (Amarox) have made an adjustment to COVIFOR’s (Remdesivir) price in Indonesia. This price adjustment is in line with Kalbe's and Amarox’s commitment to support the government initiative to combat Covid-19 pandemic and in consideration of having more patients to get COVIFOR benefits of use for the recovery from Covid-19. The price of COVIFOR, which is manufactured by Hetero India, imported by Amarox and marketed and distributed by Kalbe, which were previously announced at Rp. 3,000,000, - per vial, has been adjusted to IDR 1,500,000 per vial.

“Hetero realizes the impact of Covid-19 pandemic is extensive, especially the cost of burden for the government and patients, so Hetero extends their support and gives a specially adjusted price for Indonesia”, according to Sandeep, Country Manager of PT Amarox Global Pharma. 

“The consideration of the price adjustment of COVIFOR is based on several conditions, such as the development of the Covid-19 case in Indonesia, enormous need for treatment of Covid-19 using COVIFOR drug, inputs from Government, Healthcare Professionals, and Patients, moreover to have more patients to get COVIFOR benefits of use for the recovery from Covid-19, therefore after having a joint discussion between Kalbe, Hetero India and Amarox, we have mutually agreed to provide an adjusted selling price for COVIFOR,” said Vidjongtius, President Director of PT Kalbe Farma Tbk, “This is Kalbe’s along with Amarox’s commitment supporting the government in overcoming Covid-19 pandemic.” 

The Emergency Use Authorization of Remdesivir is for treatment or laboratory confirmed coronavirus disease 2019 (COVID-19) in adults and adolescents (aged 12 years and older with body weight at least 40 kg) patients hospitalized with severe disease.  

About Hetero
Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs. Backed by 25 years of expertise in the pharmaceutical industry, Hetero’s strategic business areas spread across APIs, generics, biosimilars, custom pharmaceutical services and branded generics. The company is globally recognized for its strengths in Research and Development, manufacturing and commercialization of a wide range of products.

Hetero has 36 state-of-the-art manufacturing facilities strategically located worldwide, approved by stringent global regulatory authorities. Our portfolio includes 300 plus products encompassing major therapeutic categories such as HIV/AIDS, Oncology, Cardiovascular, Neurology, Hepatitis, Nephrology, Urology, Diabetes, Ophthalmology, Hepatology and Immunology etc.

Hetero has a strong global presence in over 126 countries and focusses on making affordable medicines accessible to patients worldwide. 

For more, please visit www.heteroworld.com or click on LinkedIn, Twitter, Facebook

Kalbe at a glance
PT Kalbe Farma Tbk ("Kalbe") was established in 1966 and is one of the biggest public pharmaceutical companies in Southeast Asia. Kalbe has four main divisions that handle reliable and varied brand portfolio: prescription medicines (Cefspan, Hemapo, Broadced, etc.); health product division that handles over-the-counter medication (Promag, Mixagrip, Komix, Woods, Fatigon, etc.); as well as energy and ready-to-consume drinks (Extra Joss, Hydro Coco); nutrition division (ChilKid, Prenagen, Diabetasol, etc.); and distribution division. Kalbe currently has approximately 40 subsidiaries and 12 production facilities with international standard, and employs approximately 17,000 employees dispersed across more than 76 branches throughout Indonesia.  From 1991, Kalbe is listed on the Indonesia Stock Exchange (IDX: KLBF).

--oOo--


Print
390 Rate this article:
No rating

Please login or register to post comments.

Name:
Email:
Subject:
Message:
x